Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LIPE | Q05469 | 1/20 | 0.32 |
| ▸ | TK1 | P04183 | 2/20 | 0.31 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6363661 | 0.87 | ALDH1A1 (0.34) | ALDH1A1TK1BRD4 | |
| SCHEMBL6362718 | 0.80 | SMYD2 (0.33) | — | |
| SCHEMBL6364960 | 0.79 | ALDH1A1 (0.33) | ALDH1A1BRD4ADORA2AADORA1 | |
| SCHEMBL6370802 | 0.76 | ALDH1A1 (0.30) | ALDH1A1BRD4 | |
| SCHEMBL6358753 | 0.76 | TK1 (0.36) | ALDH1A1TK1SMN1; SMN2S1PR1S1PR5 | |
| SCHEMBL6364884 | 0.76 | ALDH1A1 (0.32) | ALDH1A1BRD4 | |
| SCHEMBL6553111 | 0.75 | TYMP (0.32) | — | |
| SCHEMBL7788368 | 0.75 | PDE4D (0.45) | TK1SMN1; SMN2 | |
| SCHEMBL6364693 | 0.75 | TYMP (0.34) | — | |
| SCHEMBL6364958 | 0.74 | ALDH1A1 (0.32) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900297-B1 | Amine-derivatized nucleosides and oligonucleosides | ISIS PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1487855-A2 | METHOD OF USING MODIFIED OLIGONUCLEOTIDES FOR HEPATIC DELIVERY | ISIS Pharmaceuticals, Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040142899-A1 | Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals | ISIS PHARMACEUTICALS, INC. (US) | 2004-07-22 | — | — | US | disclosed |
| US-6753423-B1 | FOR PREFERENTIALLY MODULATED GENE EXPRESSION IN LIVER AND ASSOCIATED TISSUES | ISIS PHARMACEUTICALS, INC. | 2004-06-22 | — | — | US | disclosed |
| US-20030191075-A1 | Method of using modified oligonucleotides for hepatic delivery | ISIS PHARMACEUTICALS, INC. | 2003-10-09 | — | — | US | disclosed |
| WO-2003072711-A2 | METHOD OF USING MODIFIED OLIGONUCLEOTIDES FOR HEPATIC DELIVERY | ISIS PHARMACEUTICALS, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142899-A1 | Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals | FABP1, RNASE1, RNGTT | ALDH1A1 1651/4885LIPE 2301/4885TK1 38/4885 |
| US-20030191075-A1 | Method of using modified oligonucleotides for hepatic delivery | FABP1, DCLRE1B, SLC10A1 | ALDH1A1 2822/4885LIPE 2536/4885TK1 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.